Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Hu-NSG Mice Model Development Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Studying the development of cancer cells, including signal transduction pathways and other types of cell-to-cell communication between immune cells and tumors, is essential for generating and evaluating CAR-T treatments to prevent the growth and spread of these cancer cells. To accomplish this difficult task, researchers need the best tumor model, a suitable in vivo platform, and conduct research that can accurately summarize the complex tumor microenvironment to generate translation-related data.

Breast cancer is a fatal solid tumor with the highest rate of metastasis, the worst prognosis, and limited treatment options. New research continues to push the boundary of CAR-T capabilities to treat breast cancer. Creative Biolabs has developed a research-ready humanized NSG model to test CAR-T therapy for breast cancer and can be shipped to your institution immediately or for efficacy studies at our institution.

Why humanized mice?

You may have noticed that the latest biomedical breakthroughs are using more and more humanized mice. But what is a humanized mouse and why do scientists use this type of model?

Humanized mice are usually injected with specific human stem cells that are usually derived from fetal tissue or umbilical cord blood in mice with little or no immune system. These cells produce human T cells, B cells, and other immune cells in mice, allowing scientists to explore how the human immune system attacks many diseases. Therefore, the humanized mouse can become a more powerful human model to better study the problems of human development and disease.

If you are looking for humanized mice implanted with patient-derived xenograft (PDX) tumors, Creative Biolabs offers a variety of these mice, which we call Onco-Hu™ NSG mice, breast cancer is of course included. These mice are a powerful platform conducive to proof-of-concept testing of novel immunotherapies targeting T cells or bone marrow cells. This model is dual implanted with human CD34 + HSC/PBMC.

Fig.1 Hu-NSG humanization methods.

Hu-NSG PDX/CDX Model Capabilities

Our Hu-NSG mouse models have a higher degree of immunodeficiency. It lacks NK cells while lacking T cells and B cells, and innate immunity is compromised. The Hu-NSG model is very suitable for human tumor cell transplantation (CDX), human tumor tissue transplantation (PDX) for immune reconstruction.

Highlights

• Convenient - PDX mice can be used for research and can express human immune cells.
• Consistent - every mouse has been tested for humanity.
• Stable - the implantation of hematopoietic cells provides a research platform for further research.
• License - free-no additional licensing fees or royalties.

Fig.2 Establishment of Hu-NSG PDX model for breast cancer.

In addition to the Hu-NSG breast cancer model, additional live models are also available:

• Bladder cancer
• Colon cancer
• Lung cancer
• Ovarian cancer
• Pancreatic cancer
• Prostate cancer

Applications in CAR-T Therapy Evaluation

Hu-NSG PDX model is an ideal choice for long-term in vivo research in the field of immunology and cell therapy because they have a life span of more than 12 months. Specifically, they can be used to evaluate the CAR-T therapies including but not limited to: monitor CAR-T distribution in vivo, determine CAR-T persistency, and monitor Cytokine Release Syndromes

For more detailed information, please feel free to contact us or directly sent us an inquiry.

Reference

1. Zhou, R., et al. (2019). CAR-T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.